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Do beta-blockers worsen respiratory
status for patients with COPD?
■ Evidence summary
In recent years, beta-blockers have been
shown to substantially decrease mortality 
in patients with congestive heart failure,
coronary heart disease, and hypertension.
Patients with both cardiovascular disease
and COPD, however, are much less likely
to receive beta-blocker therapy than 
comparable patients without COPD.
Clinicians may be fearful of using beta-
blockers in these patients because of the
possibility of worsening respiratory func-
tion from the potential side effect of 
bronchoconstriction.1
A 2004 meta-analysis synthesized the
data of 19 clinical controlled trials that
compared active therapy with either place-
bo or prior-to-treatment controls, assess-
ing differences in FEV1, response to a
beta2-agonist, and patient-reported respi-
ratory symptoms.2 Trials included in the
meta-analysis used cardioselective beta-
blockers and evaluated either single-dose
treatments or therapy of longer duration
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CLINICAL INQUIRIES
Patients with chronic obstructive pulmonary 
disease (COPD) who use cardioselective beta-block-
ers (beta1-blockers) do not experience a significant
worsening of their short-term pulmonary status as
measured by changes in forced expiratory volume
in 1 second (FEV1), or by changes in patients’ self-
reported symptoms. If such harmful effects do
exist, they are likely to be less clinically important
than the substantial proven benefits of beta-block-
ade for patients with concomitant cardiovascular
disease (strength of recommendation: A, based on
a high-quality meta-analysis of controlled trials). 
Limited evidence suggests that most patients
with congestive heart failure and COPD without
reversible airflow obstruction tolerate carvedilol,
which causes both nonselective beta- and alpha-
adrenergic blockade (SOR: B, based on limited-
quality cohort studies).
E V I D E N C E - B A S E D A N S W E R
Benefits outweigh risks for beta-blockade for
patients with CV disease, comorbid COPD
It appears that the benefits outweigh the risks 
for the use of cardioselective beta-blocker therapy
in patients with cardiovascular disease and
comorbid COPD. Prudent management of these
patients dictates that beta-blocker therapy should
be initiated with a low-dose cardioselective 
beta-blocker, that the respiratory status of these
patients should be monitored closely, and 
that any otherwise unexplained decline in 
respiratory status should warrant a reevaluation
of the appropriateness of beta-blocker 
therapy.
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Cardioselective
beta-blockers do
not significantly
worsen short-
term pulmonary
status in COPD
FAST TRACK
(2 days to 3.3 months). The authors 
concluded that patients with COPD who
received cardioselective beta-blockers
(such as metoprolol, atenolol, or bisopro-
lol) did not experience a statistically 
significant short-term deterioration in
FEV1, worsening of COPD symptoms, or
decreased responsiveness to beta2-
agonists. The authors reported similar
results for an analysis restricted to only
those patients with severe COPD. 
This meta-analysis was limited by the
relatively small number of participants
(N=141 in single-dose treatment studies;
N=126 in studies of longer duration treat-
ment) in the handful of eligible studies.
Consequently, rare or minimally harmful
effects could have gone undetected. 
A retrospective analysis of a cohort
study analyzed the tolerability of
carvedilol, a nonselective beta- and alpha-
adrenergic blocker, in patients with COPD
who had been taking the medication for at
least 3 months. Eighty-five percent of the
89 patients with COPD tolerated
carvedilol. The authors of the study
(which was funded by the manufacturer of
carvedilol) did not state why the other
15% of patients did not tolerate
carvedilol, nor did they mention whether
the patients with COPD had reversible
airflow obstruction.3
One of the sites that participated in
this study subsequently published a small-
er retrospective analysis of a cohort study
that examined the outcomes of 31 patients
with heart failure and COPD without
reversible airflow obstruction who were
started on carvedilol therapy. Over the 2.4
years that the patients were followed, 
1 patient stopped taking carvedilol (mean
dose 29 ± 19 mg daily) due to wheezing.4
Whether these 31 patients were also
included in the larger study is unclear. 
A 2004 narrative review article cited
these 2 studies and concluded that
carvedilol was well-tolerated in patients
with COPD without reversible airflow
obstruction, but no evidence exists regard-
ing its tolerability in patients with
reversible airflow obstruction.5
Recommendations from others
A 2002 evidence-based clinical guideline on
the diagnosis and management of COPD
reported that the use of cardioselective beta-
blockers in patients with COPD did not sig-
nificantly worsen respiratory status, citing a
previous version of the meta-analysis
reviewed above as its source of evidence.6
The American College of Cardiology and
the American Heart Association recom-
mended the cautious administration of 
low-dose, short-acting cardioselective beta-
blockers for acute coronary syndrome in
patients with COPD.7
A recent consensus workshop summary
report issued by experts convened by the
National Heart, Lung, and Blood Institute,
cited continuing uncertainty regarding the
use of beta-blockers for COPD patients
with heart disease, and called for additional
studies of management strategies for these
often-coexisting conditions.8 ■
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